When you consider how the broader cannabis stock market has been doing, though, MariMed Inc's share-price performance has been pretty decent. Wall Street analysts' average 12-month price target for MariMed stock is $2.25, which points to potential gains of 175%. (Source: “MariMed Announces Agreement to Acquire Kind Therapeutics USA, LLC, A Maryland Licensed Vertically Integrated Cannabis Business,” MariMed Inc, January 5, 2022.) (Source: “MariMed to Acquire Illinois Craft Cannabis License Allowing for Vertically Integrated Cannabis Operations,” MariMed Inc, January 18, 2022.) (Source: “MariMed Reports Third Quarter 2021 Earnings,” MariMed Inc, November 15, 2021.)

Source: Profit Confidential February 18, 2022 00:30 UTC